Adcendo ApS Announces Option License Agreement with Duality

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline

/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...

Related Keywords

Copenhagen , Køavn , Denmark , John Zhu , Michael Pehl , Novo Holdings , Duality Biologics , Duality Immune Toxin Antibody Conjugates , Option License Agreement , Chief Executive Officer , Ysios Capital , Pontifax Venture Capital , Adcendo ,